<DOC>
	<DOC>NCT02392598</DOC>
	<brief_summary>This is an epidemiologic study on effect of hepatic steatosis on prognosis and outcomes of patients with chronic hepatitis B.</brief_summary>
	<brief_title>A Hepatitis B With Hepatic Steatosis Study</brief_title>
	<detailed_description>This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients with chronic hepatisis B will be enrolled in the study and followed up after 1 year, 3 years and 5 years with a visit window of +1 month.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>1. Clinically diagnosed chronic hepatitis B. 2. Specific biopsy requirements for hepatic steatosis: qualified biopsy specimen within 6 months, &gt;5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope. 3. Willing to participate in the longterm followup and cooperative. 4. Able to provide informed consent file. 1. Unable to provide informed consent. 2. Patients are eligible for baseline analysis but not eligible for followup, if having any of the following condition: 1. Any endstage liver disease. 2. Any malignant tumor. 3. Any congenital liver disease such as Wilson disease. 4. Any other serious disease of projected survival &lt; 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>